At Hospital 57357’s annual international pediatric neurosurgery conference:Great achievements in treating pituitary gland and skull based tumors Eminent North American Pediatric Neurosurgeon, Jeffrey Wisoff: what we were able to achieve in 30 years, you have accomplished in only 10.

At the annual international conference about the latest in pediatric neurosurgery, organized and hosted by the Children’s Cancer Hospital 57357, prominent world neurosurgeons praised Hospital 57357 achievements in the field, especially in complex tumors such as Craniopharyngioma , and pituitary gland and skull based tumors. The conference was held in collaboration with experts from the Kasr El Eini Hospital, World Federation of Neurosurgical Societies, the international Society for Pediatric Neurosurgery, the Egyptian Society of Neurological surgeons with the participation of major neurosurgeons from Egypt, USA, England, France, Germany and Canada.
Dr. Wisoff, Professor at New York University shared that what they were able to achieve in 30 years in America was accomplished in only ten in Hospital 57357 .
Dr. Mohammed Albeltagy, head of neurosurgery department in 57357, reveals that in 57357, brain tumors are the second most common tumors after leukemia, which consolidates 57357’s experience in the field. “We make about 800 brain tumor surgeries annually, while major treatment centers in England make 50 surgeries in this field annually” said Dr. Albeltagy. He added that Craniopharyngioma is technically one of the most difficult brain tumors because of its location as it may be hooked to vital brain centers. Removal of such tumor would mostly affect vision, behavior or growth, which may affect the child’s quality of life in the future. The number of surgeries that were carried out in 57357 for this type of tumor during the last 10 years reached 135, with a success rate of 91%. Dr. Albeltagy qualified this performance as a remarkable achievement, when compared with Langdon Center, which is one of the biggest references for this tumor in the USA, where 138 surgeries were carried out during the last 30 years.
Dr. Albeltagy revealed that, currently, the world trend in brain tumor surgeries targets the reduction of the side effects of surgical tumor removal to contribute to improving the child’s quality of life. In this context, the latest treatment developments for craniopharyngioma depend on removing the biggest possible part of the tumor, while leaving a 1cm to 1.5cm sized part to be dealt with by radiotherapy. 57357 started embracing this technology during the past few years, and it effectively contributed to improving the results, and reducing side effects.